歸創通橋作為港股醫療器械創新龍頭，短期雖受市場情緒影響調整，但中長期成長邏輯清晰，維持看好立場。
公司基本面扎實，通橋飛龍顱內支架获批後，神經介入產品與彈簧圈形成協同，補強核心賽道佈局；國際業務已進軍52國，收入同比增36.9%，2025年預計40%的收入增速，大幅領先沛嘉醫療（25%）、微創醫療（-15%），創新與全球化雙輪驅動明確。
資金面顯示長線資金認可，GL Capital增持至6.09%，而賣空比例回落至8.96%，空頭壓力趨緩。雖當前PE 45.2倍高於行業，但高估值對應高成長，機構目標價30.67-36.4港元，潛在漲幅可觀！
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
这篇文章不错，转发给大家看看